Can Sage Therapeutics, Inc. (SAGE)'s Tomorrow Be Different? The Stock Increases Again

Friday, 08 Dec, 2017

Investors sentiment decreased to 0.98 in 2017 Q2. Its down 0.13, from 1.11 in 2017Q1.

Hedge funds have recently added to or reduced their stakes in the company. (NASDAQ:SAGE). State Board Of Administration Of Florida Retirement System owns 12,742 shares for 0% of their portfolio. (NASDAQ:SAGE). Ameritas Investment Prns Inc has invested 0.01% in Sage Therapeutics, Inc.

Nuveen Asset Ltd Liability holds 0% or 3,437 shares in its portfolio. (NASDAQ:SAGE). Susquehanna Limited Liability Partnership holds 45,032 shares or 0% of its portfolio.

Ratan Mgmt L P accumulated 1.64% or 50,000 shares. Cwm Llc owns 6 shares. (NASDAQ:SAGE) for 5,296 shares. (NASDAQ:SAGE). Parametric Portfolio Assoc Ltd Limited Liability Company holds 0% or 22,535 shares in its portfolio. Voloridge Inv Mngmt Lc stated it has 0.15% in Sage Therapeutics, Inc. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company's stock valued at $3,276,000 after purchasing an additional 3,551 shares during the period. Palo Alto Investors Ltd reported 3.84% in Sage Therapeutics, Inc. Jpmorgan Chase & Com holds 0.01% or 818,671 shares in its portfolio.

SAGE-217 was found to be safe, with no serious adverse events reported. (NASDAQ:SAGE) for 12,199 shares. The 1-year high was reported on Dec, 7 by We have $169.11 PT which if reached, will make NASDAQ:SAGE worth $393.00 million more.

The stock increased 74.90% or $68.83 during the last trading session, reaching $160.73. About 6.95M shares traded or 716.67% up from the average. (NASDAQ:SAGE) for 54,625 shares. It has outperformed by 99.75% the S&P500.

The data, according to a note from Leerink Partners analyst Paul Matteis, are a "best-case scenario" for Sage.

SAGE has been the topic of several other research reports. After $-1.97 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.52 % negative EPS growth. Therefore 88% are positive. Lake Street initiated it with "Buy" rating and $90 target in Friday, March 11 report. The company was maintained on Thursday, November 2 by RBC Capital Markets. The firm has "Buy" rating by Cowen & Co given on Thursday, August 3. SAGE Therapeutics has a 1-year low of $26.55 and a 1-year high of $75.49.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. The firm presently has a "sell" rating on the biopharmaceutical company's stock. (NASDAQ:SAGE) on Wednesday, February 22 to "Neutral" rating. Finally, BlackRock Fund Advisors boosted its position in shares of SAGE Therapeutics by 14.6% in the third quarter. Canaccord Genuity maintained it with "Buy" rating and $11000 target in Friday, August 4 report. The company was initiated on Tuesday, September 13 by Raymond James.

And for Sage, helping lift depression in patients could generate $1 billion or more in sales. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since December 7, 2016 and is uptrending.'s news article titled: "Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635 (c)(4)" with publication date: December 04, 2017 was also an interesting one. It's hard to understate how meaningful these data are in the backdrop of the very significant unmet medical need in depression: even if the SAGE data on a placebo-adjusted basis weren't differentiated via cross-trial comparisons, we still think '217 would be an important drug as it offers a new mechanism (extra-synaptic GABA-modulation) in an area where the vast majority of options generally modulate the same pathways (serotonin, dopamine, norepinephrine). Royal Bank Of Canada's price target would indicate a potential upside of 79.18% from the company's current price. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. It now has negative earnings.

Sage Therapeutics (NASDAQ:SAGE) is up 52% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.